Walmart on Tuesday launched what the retail giant says is the first-ever private brand analog insulin, which will improve access and affordability to diabetes care by offering customers a significant price savings over branded versions without compromising quality.
Available exclusively through Walmart’s private ReliOn brand, the new offering includes analog insulin vials ($72.88) and FlexPen ($85.88), which cal save customers1 between 58% to 75% off the cash price of branded analog insulin products, or a savings of up to $101 per branded vial or $251 per package of branded FlexPens.
The new private label ReliOn NovoLog Insulin (insulin aspart) injection, manufactured by Novo Nordisk, is available across the United States at Walmart pharmacies this week, and Sam’s Club pharmacies beginning in mid-July. ReliOn NovoLog is a rapid-acting insulin analog used to control high blood sugar in adults and children with diabetes. Customers will need a prescription in order to purchase the products and should consult with their doctor regarding their diabetes management.
The new private label ReliOn NovoLog Insulin (insulin aspart) injection, manufactured by Novo Nordisk, is available across the United States at Walmart pharmacies this week, and Sam’s Club pharmacies beginning in mid-July.
“We know many people with diabetes struggle to manage the financial burden of this condition, and we are focused on helping by providing affordable solutions,” said Dr. Cheryl Pegus, executive vice president, Walmart Health & Wellness. “We also know this is a condition that disproportionately impacts underserved populations. With ReliOn NovoLog insulin, we’re adding a high-quality medication for diabetes to the already affordable ReliOn line of products and continuing our commitment to improve access and lowering cost of care.”
With more than 5,000 Walmart and Sam’s Club locations in the United States, the Bentonville, Ark.-based retailer says it is a convenient destination for affordable diabetes resources, including blood glucose monitors, lancets and other diabetes management essentials in the ReliOn portfolio.
“Diabetes often comes with high medical costs, estimated around $9,601 per person per year,” added Tracey D. Brown, CEO of the American Diabetes Association. “We welcome all affordable solutions that make diabetes management more accessible to millions of Americans living with diabetes. We encourage everyone to ask their health care provider questions to better understand what the right and affordable treatment is for their unique medical needs.”
Consumers are encouraged to visit Walmart.com/diabetes for additional information about the retailer’s affordable diabetes resources.
